Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
San Francisco mayor says city in talks to bring pandas back to zoo ahead of trip to Asia - 2Interstellar comet 3I/ATLAS isn't an alien spacecraft, astronomers confirm. 'In the end, there were no surprises.'
- 3Step by step instructions to Appropriately Keep up with Your Sunlight powered chargers for Most extreme Productivity
- 4Former Australian soldier arrested over alleged Afghan war crimes
- 5UK consumer confidence plunges amid escalating Iran conflict
- 7 Heavenly Espressos, One Do You Like?
- The Most Paramount Crossroads in Olympic History
- Weather forecast, Turkana style: A goat's intestines tell it all
- How to get tickets for AC/DC's 2026 'Power Up' Tour
- 3 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- Moscow: Russia well-positioned to withstand oil market shocks
- What is a Trump Gold Card? U.S. launches $1 million immigration visas
- Lucrative Positions in the Advancing Position Market of 2024
- Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II
